etable1. STROBE Statement—Checklist of items that should be included in reports of cohort studies

| | Item No | Recommendation | Page No. |
|-------------------------|------------|---|-------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in | 1-2 |
| | | the title or the abstract | |
| | | (b) Provide in the abstract an informative and balanced | 2 |
| | | summary of what was done and what was found | |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the | 3 |
| | | investigation being reported | |
| Objectives | 3 | State specific objectives, including any prespecified | 3 |
| - | | hypotheses | |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 4-5 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including | 5-6 |
| | | periods of recruitment, exposure, follow-up, and data | |
| | | collection | |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of | 6 |
| | | selection of participants. Describe methods of follow-up | |
| | | (b) For matched studies, give matching criteria and number of | NA |
| | | exposed and unexposed | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential | 6 |
| | | confounders, and effect modifiers. Give diagnostic criteria, if | |
| | | applicable | |
| Data sources/ | 8* | For each variable of interest, give sources of data and details | 6 |
| measurement | | of methods of assessment (measurement). Describe | |
| | | comparability of assessment methods if there is more than one | |
| D | | group | |
| Bias | 9 | Describe any efforts to address potential sources of bias | NA |
| Study size | 10 | Explain how the study size was arrived at | 6 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the | NA |
| | | analyses. If applicable, describe which groupings were chosen | |
| Statistical methods | 10 | and why | 6 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to | 6 |
| | | control for confounding(b) Describe any methods used to examine subgroups and | NA |
| | | (b) Describe any methods used to examine subgroups and interactions | INA |
| | | (c) Explain how missing data were addressed | NA |
| | | (<i>d</i>) If applicable, explain how loss to follow-up was addressed | NA |
| | | (<i>a</i>) It applicable, explain now loss to follow-up was addressed (<i>e</i>) Describe any sensitivity analyses | NA |
| | | (<u>c</u>) besolve any sensitivity analyses | 11/1 |
| Results Participants | 13* | (a) Papart numbers of individuals at each store of study. | 8-11 |
| Participants | 13. | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, | 0-11 |
| | | confirmed eligible, included in the study, completing follow- | |
| | | up, and analysed | |
| | | (b) Give reasons for non-participation at each stage | NA |
| | | (c) Consider use of a flow diagram | NA |

| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 8-11 |
|-------------------|-----|---|-------|
| | | (b) Indicate number of participants with missing data for each variable of interest | NA |
| | | (c) Summarise follow-up time (eg, average and total amount) | NA |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 8-11 |
| Main results | 16 | (<i>a</i>) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | NA |
| | | (b) Report category boundaries when continuous variables were categorized | NA |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | NA |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 15 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 16-17 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 17 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 16-17 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 18 |